SEVERE ACUTE RESPIRATORY SYNDROME (SARS) TREATMENT MARKET ANALYSIS

Severe Acute Respiratory Syndrome (SARS) Treatment Market, By Drug Class (Antibiotics, Antiviral, Corticosteroids, Monoclonal antibodies, and Others), By Indication ( SARS-CoV and SARS-CoV-2) , By Route of Administration (Oral and Intravenous), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region/Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI4494
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Severe Acute Respiratory Syndrome (SARS) Treatment Market – Regional Insights

North America was found to dominate the market growth, owing to the number of drug approvals for the treatment of COVID-19 in hospitals. For instance, FDA approved Remdesivir in November 2020 manufactured by Gilead sciences, a biopharmaceutical company focused on manufacturing antiviral drugs, as the first treatment against COVID-19 disease.

Asia Pacific is expected to show lucrative growth during the forecast period, owing to increased production of drugs for COVID-19 treatment by market players in order to combat the pandemic. For instance in May 2020, almost 70 metric tons of Hydroxychloroquine was manufactured in India by Zydus Cadila, and Ipca laboratories, and exported to neighboring countries along with the U.S. Zydus Cadila and Ipca labs are international pharmaceutical companies that manufacture generic drugs and active pharmaceutical ingredients respectively.

By Region